merck & co. inc.
(MRK:New York Consolidated)
Transactions by MERCK & CO. INC. (MRK) in the last 6 months
American Industrial Acquisition Corporation signed an agreement to acquire the manufacturing facility in Arecibo from Merck & Co. Inc. (NYSE:MRK) on April 9, 2015. American Industrial Acquisition Corporation will retain the approximately 200 Merck employees at the Arecibo manufacturing facility.
Arvinas, Inc. announced that it will receive funding from new investor Merck & Co., Inc. on April 7, 2015. The terms of the transaction were not disclosed.
Merck & Co. Inc. (NYSE:MRK) announces a share repurchase program. Under the program, the company will repurchase up to $10,000 million worth of common stock. The repurchases will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The shares will be repurchased for its treasury. The program reinforces company's commitment to deliver increased value to the shareholders and the Board's confidence ...
NGM Biopharmaceuticals, Inc. announced that it will receive $106 million from new investor Merck & Co. Inc. on February 23, 2015. The investor will acquire 15% stake in the company. The round will be raised at a post-money valuation of $706 million. The funding raised will represent 20% premium to NGM’s most recent financing. The company has issued convertible series E preferred stock Pursuant to Regulation D.
Merck & Co. Inc. (NYSE:MRK) acquired OncoEthix SA from Index Ventures, Edmond de Rothschild Investment Partners, S.A.S., Endeavour II of Endeavour Vision SA, SV Life Sciences Advisers, LLC, and others for approximately $380 million on December 18, 2014. Under the terms of transaction, Merck shall make an upfront payment of up to $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being ...
Edmond de Rothschild Investment Partners, S.A.S.
Endeavour Vision SA
SV Life Sciences Advisers, LLC
Merck & Co. Inc. entered into a definitive agreement to acquire Cubist Pharmaceuticals Inc. (NasdaqGS:CBST) from Bellevue Asset Management AG, Deutsche Asset & Wealth Management Investment GmbH, Federated Equity Management Company of Pennsylvania, HBM Partners Ltd.,Tekla Healthcare Investors and Tekla Life Sciences Investors, funds of Tekla Capital Management LLC, and others for $7.8 billion in cash on December 8, 2014. Merck will acquire the shares of Cubist for $102 ...
Deutsche Asset & Wealth Management Investment GmbH
Federated Equity Management Company of Pennsylvania
HBM Partners Ltd.
Tekla Capital Management LLC
Tekla Healthcare Investors
Tekla Life Sciences Investors
Morgan Stanley & Co. LLC
Ropes & Gray LLP
Merial Limited agreed to acquire the Merck manufacturing facility in Barceloneta, Puerto Rico from Merck & Co. Inc. (NYSE:MRK) on December 4, 2014. The proposed transaction requires approval from the United States Federal Trade Commission. If approved, the acquisition will allow Merial to expand its global manufacturing operations and make use of the site's expertise in chewables manufacturing technology. As part of the agreement, Merial will retain the approximately ...
|3M Co||$161.02 USD||+1.43|
|Gilead Sciences Inc||$112.46 USD||+2.69|
|GlaxoSmithKline PLC||1,445 GBp||+15.00|
|L'Oreal SA||€177.65 EUR||+4.05|
|Pfizer Inc||$34.30 USD||+0.19|
|View Industry Companies|